Aveo pharmaceuticals, inc. (AVEO)
Balance Sheet / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Dec'10
Assets
Current assets:
Cash and cash equivalents

23,457

29,785

57,654

40,232

23,483

24,427

20,408

18,089

16,160

14,949

16,354

30,860

33,411

15,096

12,370

25,331

18,056

26,634

34,739

26,766

34,535

52,306

59,980

43,362

46,335

50,826

50,420

33,822

85,898

76,134

114,103

85,789

73,065

43,506

45,913

81,013

45,791

Marketable securities

10,163

17,960

-

-

-

-

-

-

10,835

18,576

21,055

9,267

-

8,252

18,461

14,200

5,749

7,501

2,500

-

4,534

0

3,413

21,575

41,987

67,680

79,942

122,348

105,736

84,468

75,589

130,105

151,262

177,622

213,915

183,295

94,407

Tenant improvement allowance receivable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

196

14,900

13,321

5,833

-

-

-

3,240

-

-

-

-

-

-

-

Restricted cash

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

4,000

-

2,863

2,862

2,960

2,997

2,997

687

636

598

-

-

-

-

-

-

-

-

-

-

-

Accounts receivable

2,779

1,631

1,090

611

2,571

3,026

344

973

600

402

2,375

445

676

1,027

990

1,302

1,736

4,641

2,334

2,320

947

2,341

1,658

1,235

1,254

984

8,893

7,897

9,181

20,649

9,298

9,182

9,489

7,210

9,747

28,770

391

Insurance recovery (Note 13)

-

-

-

-

-

-

-

-

15,000

15,000

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Clinical trial retainers

402

589

200

18

42

126

284

567

836

1,027

1,274

1,274

1,702

1,702

-

-

-

467

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other prepaid expenses and other current assets

263

635

816

801

199

356

402

370

171

229

470

294

110

238

2,203

1,421

-

1,133

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Prepaid expenses and other current assets

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,123

-

1,364

1,428

1,440

1,484

3,259

3,665

2,044

2,998

7,232

9,217

9,744

6,190

7,770

5,208

3,487

6,057

5,559

9,294

4,864

Total current assets

37,064

50,600

59,760

41,662

26,295

27,935

21,438

19,999

43,602

50,183

41,528

42,140

35,899

26,315

34,024

42,254

30,664

40,376

43,800

33,376

44,416

59,128

71,503

85,424

105,577

128,919

146,487

173,284

210,559

190,681

206,760

230,284

237,303

234,395

275,134

302,372

145,453

Marketable securities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

20,505

54,312

36,526

32,476

-

Property and equipment, net

100

-

-

-

-

-

-

-

-

-

-

-

-

-

23

22

18

23

52

131

5,372

11,295

14,685

15,863

19,011

14,140

12,766

13,238

13,331

12,867

7,862

6,626

6,032

5,471

5,163

5,008

4,532

Operating lease right-of-use asset

1,225

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Clinical trial retainers

-

-

-

-

-

-

-

-

-

-

165

330

659

940

-

-

-

117

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other assets

158

-

-

-

212

-

4

7

11

15

18

22

26

30

1,071

410

124

26

164

188

213

239

45

97

258

290

303

330

367

321

308

356

98

121

230

230

456

Restricted cash

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

2,863

2,959

2,997

3,558

3,558

3,558

3,600

3,600

3,600

751

751

705

705

607

Total assets

38,547

50,600

59,760

41,662

26,507

27,935

21,442

20,006

43,613

50,198

41,711

42,492

36,584

27,285

35,118

42,686

30,806

40,542

44,016

33,695

50,001

70,662

86,233

104,247

127,805

146,346

163,114

190,410

227,815

207,469

218,530

240,866

264,689

295,050

317,758

340,791

151,048

Liabilities and stockholders’ equity
Current liabilities:
Accounts payable

2,965

1,466

2,183

1,963

2,109

3,499

2,983

2,822

3,380

2,436

1,941

3,361

3,277

2,186

1,179

2,079

340

1,425

290

1,567

2,619

3,245

1,654

3,500

4,031

4,238

6,137

7,230

8,083

10,628

10,259

4,276

7,555

8,904

9,678

12,938

9,247

Accrued clinical trial costs and contract research

5,100

5,680

5,099

4,708

6,352

6,254

7,253

6,991

7,337

8,321

7,496

6,243

5,144

3,998

-

-

-

1,966

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accrued contract research

-

-

-

-

-

-

-

-

-

-

-

-

-

-

2,824

2,772

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other accrued liabilities

1,476

2,336

1,805

1,555

2,132

2,698

3,190

1,684

1,962

2,458

1,621

1,360

1,268

1,531

1,525

1,453

-

2,140

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Operating lease liability

438

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accrued expenses

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

2,843

-

5,453

4,551

6,393

9,301

7,102

16,193

12,351

13,263

12,154

14,314

18,067

19,543

18,358

21,259

14,622

14,289

13,297

10,277

10,121

Lease exit obligation

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,835

4,981

7,798

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Loans payable, net of discount

9,876

9,569

9,257

8,178

5,688

3,254

4,256

2,388

586

-

4,920

3,055

3,539

2,124

766

-

3,019

2,053

4,217

7,985

9,878

11,722

7,954

11,096

10,730

10,383

10,043

9,709

9,384

6,809

4,334

1,946

-

8,551

6,142

6,039

5,766

Deferred revenue

1,974

1,974

1,974

1,974

1,974

1,658

1,342

1,342

-

395

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred revenue

-

-

-

-

-

-

-

-

1,342

-

395

395

481

510

510

660

660

814

457

384

461

537

332

1,128

2,897

1,294

1,294

1,294

1,294

1,294

1,294

1,294

1,294

1,294

1,294

2,230

16,693

Deferred research and development reimbursements

210

93

213

207

336

454

463

534

706

901

935

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Estimated settlement liability (Note 13)

-

-

-

-

-

-

-

1,406

17,115

17,073

-

-

-

-

4,000

4,000

4,000

4,000

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other liabilities (Note 6)

-

-

300

300

300

300

-

-

-

540

540

540

540

-

-

-

-

-

-

-

-

-

-

-

1,238

1,238

1,238

1,238

-

-

-

-

1,249

1,249

1,249

1,249

-

Deferred rent

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

5,369

10,569

14,041

1,080

1,397

992

864

903

918

856

421

356

329

322

260

268

266

Total current liabilities

22,039

21,118

20,831

18,885

18,891

18,117

19,487

17,167

32,428

32,124

17,848

14,954

14,249

10,349

6,804

6,964

10,862

12,398

10,417

14,487

26,555

40,355

38,881

32,997

32,644

31,408

31,730

34,688

37,746

39,130

34,666

29,131

25,049

34,609

31,920

33,001

42,093

Loans payable, net of current portion and discount

3,610

6,197

8,714

11,166

13,511

15,779

14,621

16,342

18,002

18,477

14,324

16,067

10,599

11,879

13,103

13,735

6,537

7,418

8,260

7,316

8,139

8,930

12,491

3,088

6,001

8,822

11,549

14,184

16,731

19,228

21,624

23,933

25,800

15,619

17,900

17,815

17,636

Deferred revenue

2,059

2,552

3,045

3,539

4,032

3,802

3,414

3,749

-

1,302

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred revenue

-

-

-

-

-

-

-

-

4,085

-

1,401

1,499

1,598

1,697

1,824

2,666

2,832

2,881

884

-

-

231

51

128

204

17,098

17,421

17,744

18,067

18,391

18,714

19,037

19,361

19,684

20,008

20,331

16,509

Deferred research and development reimbursements

-

-

20

-

-

-

65

118

143

222

459

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

PIPE Warrant liability (Note 7)

2,449

5,097

7,603

5,649

7,859

16,674

43,157

26,985

38,110

37,746

51,953

29,002

5,077

4,593

9,162

10,340

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Operating lease liability, non-current

592

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred rent, net of current portion

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

13,430

21,198

19,080

16,604

14,888

12,851

10,544

4,096

1,695

334

359

394

446

553

Other liabilities (Note 6)

790

790

790

790

790

790

1,090

1,090

1,090

1,090

300

300

150

690

690

690

660

618

577

656

713

540

540

-

-

-

-

-

1,238

1,238

1,238

1,238

1,238

1,238

1,238

1,238

2,487

Total liabilities

31,539

35,754

41,003

40,029

45,083

55,162

81,834

65,451

93,858

90,961

86,285

61,822

31,673

29,208

31,583

34,395

-

23,315

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Commitments and contingencies (Note 8)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

0

-

-

-

0

-

-

-

0

-

-

0

Lease exit obligation, net of current portion

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

7,646

3,492

-

-

-

-

-

-

-

-

-

-

-

-

Stockholders’ equity:
Preferred stock, $.001 par value: 5,000 shares authorized at March 31, 2020 and December 31, 2019; no shares issued and outstanding at each of March 31, 2020 and December 31, 2019

-

-

-

-

-

-

0

0

0

-

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

Common stock, $.001 par value: 50,000 shares authorized at March 31, 2020 and December 31, 2019; 16,081 shares issued and outstanding at each of March 31, 2020 and December 31, 2019

161

161

161

161

139

126

121

119

119

118

118

117

110

76

76

76

58

58

58

56

55

52

52

52

52

52

52

52

52

44

44

44

44

43

43

43

36

Additional paid-in capital

600,849

600,306

599,756

599,060

575,738

567,655

556,314

549,099

548,308

546,092

545,774

544,626

535,584

519,911

519,742

519,550

512,594

512,201

512,259

507,538

505,441

500,582

500,352

498,602

497,946

497,177

496,314

495,147

495,461

439,173

436,937

434,437

431,915

429,531

427,248

424,732

308,268

Accumulated other comprehensive income

-

-

-

1

1

1

-

1

-4

-4

2

-2

1

6

28

10

2

-3

1

-

0

-

-

2

7

-2

8

-35

14

-19

-9

9

60

-167

-296

64

-20

Accumulated deficit

-594,002

-585,621

-581,160

-597,589

-594,454

-595,009

-616,827

-594,664

-598,668

-586,969

-590,468

-564,071

-530,784

-521,916

-516,311

-511,345

-502,739

-495,029

-488,440

-496,358

-490,902

-480,028

-466,134

-451,698

-433,739

-427,289

-410,564

-386,258

-354,345

-320,260

-298,780

-268,658

-239,112

-205,866

-180,697

-156,879

-236,514

Total stockholders’ equity

7,008

14,846

18,757

1,633

-18,576

-27,227

-60,392

-45,445

-50,245

-40,763

-44,574

-19,330

4,911

-1,923

3,535

8,291

9,915

17,227

23,878

11,236

14,594

20,606

34,270

46,958

64,266

69,938

85,810

108,906

141,182

118,938

138,192

165,832

192,907

223,541

246,298

267,960

71,770

Total liabilities and stockholders’ equity

38,547

50,600

59,760

41,662

26,507

27,935

21,442

20,006

43,613

50,198

41,711

42,492

36,584

27,285

35,118

42,686

30,806

40,542

44,016

33,695

50,001

70,662

86,233

104,247

127,805

146,346

163,114

190,410

227,815

207,469

218,530

240,866

264,689

295,050

317,758

340,791

151,048